342 related articles for article (PubMed ID: 29316830)
1. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
2. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
Wei C; Ni W; Cai X; Cui J
Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
[TBL] [Abstract][Full Text] [Related]
3. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
[TBL] [Abstract][Full Text] [Related]
4. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
[TBL] [Abstract][Full Text] [Related]
5. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.
Daly MW; Riddle DJ; Ledeboer NA; Dunne WM; Ritchie DJ
Pharmacotherapy; 2007 Jul; 27(7):1052-7. PubMed ID: 17594211
[TBL] [Abstract][Full Text] [Related]
7. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
[TBL] [Abstract][Full Text] [Related]
8. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
[TBL] [Abstract][Full Text] [Related]
9. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient.
Rodríguez-Avial C; Rodríguez-Avial I; Merino P; Picazo JJ
Clin Microbiol Infect; 2012 Jan; 18(1):61-6. PubMed ID: 21722259
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.
Goessens WH; Mouton JW; Ten Kate MT; Sörgel F; Kinzig M; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2013 Jan; 57(1):643-6. PubMed ID: 23129049
[TBL] [Abstract][Full Text] [Related]
11. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Spanu T; De Angelis G; Cipriani M; Pedruzzi B; D'Inzeo T; Cataldo MA; Sganga G; Tacconelli E
Antimicrob Agents Chemother; 2012 Aug; 56(8):4516-8. PubMed ID: 22644031
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Kang Y; Zhou Q; Cui J
J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
[TBL] [Abstract][Full Text] [Related]
14. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.
Al-Qadheeb NS; Althawadi S; Alkhalaf A; Hosaini S; Alrajhi AA
Ann Saudi Med; 2010; 30(5):404-7. PubMed ID: 20697161
[TBL] [Abstract][Full Text] [Related]
15. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility.
Roy S; Datta S; Viswanathan R; Singh AK; Basu S
J Antimicrob Chemother; 2013 May; 68(5):1036-42. PubMed ID: 23335112
[TBL] [Abstract][Full Text] [Related]
17. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections: a critical agenda.
De Rosa FG; Corcione S; Cavallo R; Di Perri G; Bassetti M
Future Microbiol; 2015; 10(2):283-94. PubMed ID: 25689539
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
[TBL] [Abstract][Full Text] [Related]
20. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
